Drawing the 'Line of Life Extension': 2021 China Precision Immuno-Oncology Forum and Yuanzhi TianTi Institute Upgrade Launch
In the broader context of precision medicine, tumor immunotherapy is flourishing. The second decade of the 21st century witnessed the most rapid advancements in immunotherapy: novel cancer treatment modalities, such as immune checkpoint inhibitors targeting PD-1 and CAR-T cell therapy, have successfully translated from research achievements to clinical applications; multiple PD-1/PD-L1 inhibitors and CAR-T therapies have received regulatory approval; CAR-T therapy is making significant inroads into the challenging realm of solid tumor treatment; and oncolytic viruses as well as neoantigen-based novel cancer immunotherapies are developing with remarkable momentum.
However, research in tumor immunotherapy is a complex, interdisciplinary, and systematic endeavor. To further promote the exchange and development of cutting-edge technologies in the field of oncology treatment in China,January 23, Yuanzhi Technology and Yuce Bio joined forces with VCBeat to jointly launch this2021 China Forum on the Development of Precision Immuno-Oncology Diagnosis and Treatment & Launch Event for the Upgrade of Yuanzhi Tianladder Institute of Precision OncologyThis event will foster collaboration between academia and industry, focusing on the field of precision immuno-oncology diagnosis and treatment. By leveraging industrial strengths, it aims to facilitate the integration of resources across clinical practice, scientific research, enterprises, and capital, thereby driving the comprehensive upgrade of the Yuanzhi Tianladder Institute for Precision Oncology.
The forum will begin with a macro-level overview of the oncology immunotherapy landscape and focus on micro-level advances in tumor immune diagnosis, treatment, and innovative progress. The event is divided into:Panoramic View of Oncology Immunology R&D, Advanced Roadmap for Oncology Immunology, New Pivots in Oncology Immunology Diagnosis and Treatment, New Wave in Oncology Immunology R&DFour Sections. FromClinical, Industry, InvestmentDistinguished experts will provide a comprehensive, multi-dimensional analysis of the new journey in tumor cell diagnosis and treatment, covering advancements in precision diagnostics and therapeutics, innovative drug development, applications of emerging digital technologies, industrial capital allocation, and the progression of industry-academia-research collaboration.
In response to the current fragmented and disjointed state of immunotherapy research, the Yuanzhi TianTi Institute for Precision Oncology Medicine will further upgrade its initiatives at the conference, withMarket-oriented approachOptimizing the Allocation of Resources in Tumor Immunology Research, establishA Think Tank of Tumor Immunology Experts with a Global PerspectiveandThe Largest Real-World Study on Tumor Immunotherapy, provide top-level design for research and clinical practice in tumor immunotherapy from a global perspective, guide innovative collaboration among multiple stakeholders including scientific researchers, clinicians, pharmaceutical companies, and investors, accelerate both the quantity and quality of output, and facilitate the translation of achievements to various market entities.
Event Date: January 23, 2021 (Saturday)
Venue: Hilton Guangzhou Baiyun (No. 515-517, Yuncheng East Road, Baiyun District, Guangzhou, China)
Event Theme: The Lifeline of Extended Life
Scan QR Code to Register